Floatz logo

Resmetirom

HIV (Human Immunodeficiency Virus)

Naga P. ChalasaniSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

61 Active assets in the HIV (Human Immunodeficiency Virus) cohort.

Asset / SponsorPhaseRating
Raltegravir
Helsinki University Central Hospital
Phase 4A
ZIDOVUDINE
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BBB
Efavirenz
The Cleveland Clinic
Phase 4BBB
Ganciclovir
Phase 4BBB
RITONAVIR
Giovanni Di Perri
Phase 4BBB

View all 50 →

Same molecule, other indications

Resmetirom is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
BBB
Indicative ·
78 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
B
Indicative ·
62 / 100
View asset →
cirrhosis of liverDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →